Company: GIFLF
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001104659-25-034245
Chunk: 112

Company: Grifols SA
Filing Date: 2025-04-11
Form: 20-F
Item: Item 4
Chunk 112
---
 patents and patent applications related to our Diagnostic products and Healthcare Solutions business line, including 319 in Europe, 93 in the United States and Canada and 140 in the rest of the world. The most important of these patents relate to the:

●   BlisPack®, a blister handling machine;
------------------------------------------

●   Erytra Eflexis®, a mid-sized instrument to perform pre-transfusion compatibility tests using DG Gel® technology;
--------------------------------------------------------------------------------------------------------------------

●   innovative containers for human plasma proteins;
----------------------------------------------------

●   novel HIV antigens for blood screening;
-------------------------------------------

●   soluble recombinant form of CD38 receptor;
----------------------------------------------

●   soluble recombinant form of CD47 receptor;
----------------------------------------------

●   recombinant antigens for detection of COVID-19; and
-------------------------------------------------------
72

●   multiplex technology for molecular detection.
-------------------------------------------------
Licenses from Third Parties
We license certain intellectual property rights from third parties, including Singulex and Hologic. Singulex granted us an exclusive worldwide license under certain intellectual property rights for the use and sale of certain products and services for blood donor and plasma screening. Pursuant to an intellectual property license with Hologic, we obtained a fully paid-up license to certain of Hologic’s intellectual property for use in the NAT Donor Screening Unit.
Licenses from Government Authorities
Government authorities in the United States, at the federal, state and local level, and in other countries throughout the European Union, Latin America, Asia and elsewhere, through licenses, approvals, reviews, inspections and other requirements, extensively regulate the research, development, testing, approval, manufacturing, labeling, post-approval monitoring and reporting, packaging, promotion, storage, advertising, distribution, marketing and export and import of healthcare products such as those that we collect, manufacture, sell or are currently developing.
For example, in order to sell our plasma derivative products we must hold appropriate product licenses from applicable governmental authorities. We have 1,101 Biopharma product licenses registered in 90 countries, which include the licenses we hold from the FDA for the sale in the United States of IG, A1PI, albumin, Factor VIII, Factor IX, ATIII and PTC. The production, marketing and sale of many of our Diagnostic business unit products are subject to the prior registration of such products with the relevant authorities of the applicable jurisdictions. We have 3,643 diagnostic product licenses registered in a total of 81 countries in Europe, the United States, Canada, Latin America, Oceania